Precision Medicine & Biomarkers Leaders Summit

    1380

    Start date: May 7, 2018

    End date: May 8, 2018

    Location: Boston, MA.

    International

    Precision Medicine & Biomarkers Leaders Summit – a key senior level R&D event confirmed to take place on May 7-8, 2018 in Boston, MA.

    Participating Organizations.

    • Abbvie
    • Aevi Genomic Medicine Inc
    • Agenus
    • Agenus Inc
    • Amgen
    • AstraZeneca
    • Berg
    • BioPartner UK
    • BlackThorn Therapeutics
    • Celgene
    • Datavant
    • Eisai
    • Eli Lilly
    • EMD Serono
    • Genocea Biosciences
    • Gilead Sciences
    • HeritX
    • Human Longevity
    • Incyte Corporation
    • Ischemia Care
    • LEO Science & Tech Hub
    • Merck
    • Merrimack Pharmaceuticals
    • Novartis
    • NuMedii Inc.
    • Pangea Diagnostics
    • Pfizer
    • Pharma Licensing
    • Puma Biotechnology
    • Rafael Pharma
    • Regeneron Pharmaceuticals
    • Takeda
    • Teva

    This an interactive meeting and the insights that you could bring would provide some invaluable input! So why not come and join us and contribute to these important topic areas:

    • Strategies and Technologies to Deliver Precision Medicine
    • Clinical & Translational Biomarkers
    • Companion Diagnostics Partnerships & Development
    • Immuno-Oncology & Liquid Biopsies

    There are also opportunities to actively take part in the meeting as part of a panel discussion or roundtable. Do let me know if this would be of interest to you.

    Our European 2017 meeting attracted over 200 attendees and was extremely well received – You can view the 2018 US agenda schedule synopsis and further details at –

    http://www.global-engage.com/wp-content/uploads/2018/01/Precision-Medicine-USA-Agenda-18.pdf

    This invitation provides you with complimentary registration to the meeting which includes 2 conference tracks, interactive panel discussions, over 20 exhibitors showcasing the latest products and technologies as well as a networking drinks receptions and dinner after the close of the first day’s proceedings.